tiprankstipranks
Advertisement
Advertisement

AU:ATH Stock Latest News

Alterity advances ATH434 toward Phase 3 in Multiple System Atrophy after FDA backing
Company AnnouncementsAlterity advances ATH434 toward Phase 3 in Multiple System Atrophy after FDA backing
6d ago
Alterity Therapeutics Sets Virtual General Meeting for May 29, 2026
PremiumCompany Announcements
Alterity Therapeutics Sets Virtual General Meeting for May 29, 2026
6d ago
Alterity Therapeutics receives FDA feedback after second ATH434 Type C meeting
PremiumThe Fly
Alterity Therapeutics receives FDA feedback after second ATH434 Type C meeting
8d ago
ATHE
Alterity Wins FDA Backing on CMC Plan for ATH434 Phase 3 in Multiple System Atrophy
PremiumCompany Announcements
Alterity Wins FDA Backing on CMC Plan for ATH434 Phase 3 in Multiple System Atrophy
9d ago
Alterity Therapeutics presents new data analyses from ATH434 trial
PremiumThe Fly
Alterity Therapeutics presents new data analyses from ATH434 trial
13d ago
ATHE
Alterity’s ATH434 Shows Phase 2 Efficacy Signal in MSA on New Composite Scale
PremiumCompany AnnouncementsAlterity’s ATH434 Shows Phase 2 Efficacy Signal in MSA on New Composite Scale
14d ago
Alterity Therapeutics Names Ann Cunningham to Board With No Initial Shareholding
Premium
Company Announcements
Alterity Therapeutics Names Ann Cunningham to Board With No Initial Shareholding
15d ago
Alterity Therapeutics Grants 27 Million Unlisted Options Under Incentive Scheme
Premium
Company Announcements
Alterity Therapeutics Grants 27 Million Unlisted Options Under Incentive Scheme
15d ago
Alterity Therapeutics Issues 212 Million Unlisted Options Under Employee Incentive Plan
PremiumCompany Announcements
Alterity Therapeutics Issues 212 Million Unlisted Options Under Employee Incentive Plan
15d ago
Alterity Therapeutics appoints Cunningham to Board of Directors
PremiumThe Fly
Alterity Therapeutics appoints Cunningham to Board of Directors
18d ago
ATHE
Alterity Therapeutics Adds Veteran Biotech Executive Ann Cunningham to Board
PremiumCompany Announcements
Alterity Therapeutics Adds Veteran Biotech Executive Ann Cunningham to Board
19d ago
Alterity to Spotlight ATH434 MSA Data in Late-Breaker at AAN Meeting
PremiumCompany Announcements
Alterity to Spotlight ATH434 MSA Data in Late-Breaker at AAN Meeting
19d ago
Alterity Therapeutics Showcases ATH434 Progress in Virtual MSA KOL Event
PremiumCompany AnnouncementsAlterity Therapeutics Showcases ATH434 Progress in Virtual MSA KOL Event
21d ago
Alterity Flags Risks Around Forward‑Looking Corporate Outlook
Premium
Company Announcements
Alterity Flags Risks Around Forward‑Looking Corporate Outlook
1M ago
Alterity Therapeutics receives regulatory feedback from FDA regarding ATH434
Premium
The Fly
Alterity Therapeutics receives regulatory feedback from FDA regarding ATH434
1M ago
ATHE
Alterity Wins FDA Backing on Key Elements of ATH434 Phase 3 Plan
PremiumCompany Announcements
Alterity Wins FDA Backing on Key Elements of ATH434 Phase 3 Plan
1M ago
Alterity Therapeutics to Issue 61.5 Million Unlisted Options Under Incentive Plan
PremiumCompany Announcements
Alterity Therapeutics to Issue 61.5 Million Unlisted Options Under Incentive Plan
1M ago
Alterity Therapeutics Plans Issue of 150 Million Options on ASX
PremiumCompany Announcements
Alterity Therapeutics Plans Issue of 150 Million Options on ASX
2M ago
Alterity Therapeutics Launches Facility to Sell Small Share Parcels
PremiumCompany Announcements
Alterity Therapeutics Launches Facility to Sell Small Share Parcels
2M ago
Alterity Therapeutics Highlights Late-Stage Neurodegenerative Pipeline at Bell Potter Summit
PremiumCompany AnnouncementsAlterity Therapeutics Highlights Late-Stage Neurodegenerative Pipeline at Bell Potter Summit
2M ago
Alterity Therapeutics appoints Daniel Claasen as chief medical advisor
Premium
The Fly
Alterity Therapeutics appoints Daniel Claasen as chief medical advisor
2M ago
ATHE
Alterity Therapeutics Taps Vanderbilt Neurologist as Chief Medical Advisor Ahead of Phase 3 MSA Trial
Premium
Company Announcements
Alterity Therapeutics Taps Vanderbilt Neurologist as Chief Medical Advisor Ahead of Phase 3 MSA Trial
2M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >